These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32432841)

  • 1. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN
    Haemophilia; 2020 Nov; 26(6):1038-1045. PubMed ID: 32432841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers.
    Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN
    Orphanet J Rare Dis; 2019 Nov; 14(1):256. PubMed ID: 31727111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
    J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.
    Al-Samkari H; Kasthuri RS; Parambil JG; Albitar HA; Almodallal YA; Vázquez C; Serra MM; Dupuis-Girod S; Wilsen CB; McWilliams JP; Fountain EH; Gossage JR; Weiss CR; Latif MA; Issachar A; Mei-Zahav M; Meek ME; Conrad M; Rodriguez-Lopez J; Kuter DJ; Iyer VN
    Haematologica; 2021 Aug; 106(8):2161-2169. PubMed ID: 32675221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.
    Buscarini E; Botella LM; Geisthoff U; Kjeldsen AD; Mager HJ; Pagella F; Suppressa P; Zarrabeitia R; Dupuis-Girod S; Shovlin CL;
    Orphanet J Rare Dis; 2019 Feb; 14(1):28. PubMed ID: 30717761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
    Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
    Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series.
    Rosenberg T; Fialla AD; Kjeldsen J; Kjeldsen AD
    Rhinology; 2019 Aug; 57(4):242-251. PubMed ID: 30907391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How I treat bleeding in hereditary hemorrhagic telangiectasia.
    Al-Samkari H
    Blood; 2024 Aug; 144(9):940-954. PubMed ID: 38864625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for Clinicians.
    Al-Samkari H
    Semin Thromb Hemost; 2022 Jul; 48(5):514-528. PubMed ID: 35226946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
    Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
    JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
    Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
    Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia].
    Xu C; Wang HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jun; 51(6):476-9. PubMed ID: 27345893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?
    Dupuis-Girod S; Shovlin CL; Kjeldsen AD; Mager HJ; Sabba C; Droege F; Fargeton AE; Fialla AD; Gandolfi S; Hermann R; Lenato GM; Manfredi G; Post MC; Rennie C; Suppressa P; Sure U; ; Buscarini E
    Eur J Med Genet; 2022 Oct; 65(10):104575. PubMed ID: 35940549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia.
    Zarrabeitia R; Ojeda-Fernandez L; Recio L; Bernabéu C; Parra JA; Albiñana V; Botella LM
    Thromb Haemost; 2016 Jun; 115(6):1167-77. PubMed ID: 26818701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary haemorrhagic telangiectasia: to transplant or not to transplant - is there a right time for liver transplantation?
    Muller YD; Oppliger R; Breguet R; Meyer P; Rubbia-Brandt L; Petignat PA; Harr T; Dayer E; Seebach JD
    Liver Int; 2016 Dec; 36(12):1735-1740. PubMed ID: 27864873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hereditary hemorrhagic telangiectasia (OslerWeberRendu syndrome) - Part II. Pharmacological therapy and international guidelines for the therapy 2020].
    Adam Z; Brančiková D; Romanová G; Pour L; Krejčí M; König J; Nebeský T; Adamová Z; Štork M; Krejčí M; Ševčíková S; Eid M; Sandecká V; Král Z
    Vnitr Lek; 2021; 67(7):419-424. PubMed ID: 35459360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Hereditary Haemorrhagic Telangiectasia with Bevacizumab - What More Needs to be Known?
    Morrissey E; Schmidt-Martin D; Buckley M
    Eur J Case Rep Intern Med; 2024; 11(1):004219. PubMed ID: 38223286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
    Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
    JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report.
    Ospina FE; Echeverri A; Posso-Osorio I; Jaimes L; Gutierrez J; Tobón GJ
    Colomb Med (Cali); 2017 Jun; 48(2):88-93. PubMed ID: 29021642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review.
    Kini SD; Yiu DW; Weisberg RA; Davila JF; Chelius DC
    Ann Otol Rhinol Laryngol; 2019 May; 128(5):467-471. PubMed ID: 30693788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.